Kyowa Kirin, a specialty pharmaceutical company, will acquire Orchard Therapeutics, a company involved in gene therapy, for $387.4 million.  The acquisition will allow Kyowa Kirin to maximize the value of Libmeldy and efficiently accelerate the development of Orchard Therapeutics’ next-in-line MPS programs, as well as its  early research programs, including a severe, genetic form of Crohn’s disease and frontotemporal dementia (FTD). Furthermore, the combination of Orchard Therapeutics&#821...